Literature DB >> 26821326

[Thymus cancers: A clinical observation].

H Grosch1, H Hoffmann2, C-A Weis3, M Thomas4.   

Abstract

INTRODUCTION: Thymic tumors including thymomas, thymic carcinomas, and thymic carcinoid tumors are rare tumors with an incidence of 0.13/100,000.
MATERIALS AND METHODS: A literature search was performed to identify recent findings on epidemiology, classification, and various therapeutic approaches.
RESULTS: These tumors with a wide spectrum of histologic and biologic features may be clinically unapparent for a long time or show a very aggressive behavior with local invasion and distant metastases. Surgical resection is the mainstay in stage I and II thymomas, whereas in stage III thymomas and in thymomas with pleural dissemination surgery in context of a multimodal treatment should be discussed. Thymic tumors are chemoreactive. Targeted therapies show poor results and should only be considered in the palliative situation after failure of chemotherapy.
CONCLUSION: The new TNM (T: tumor, N: node, M: metastasis) classification of thymic tumors will help to identify the best treatment options.

Entities:  

Keywords:  Carcinoma, thymic; Myasthenia gravis; Paraneoplastic syndromes; Thymic carcinoid tumor; Thymoma

Mesh:

Year:  2016        PMID: 26821326     DOI: 10.1007/s00292-016-0140-5

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  26 in total

1.  The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors.

Authors:  Frank C Detterbeck; Kelly Stratton; Dorothy Giroux; Hisao Asamura; John Crowley; Conrad Falkson; Pier Luigi Filosso; Aletta A Frazier; Giuseppe Giaccone; James Huang; Jhingook Kim; Kazuya Kondo; Marco Lucchi; Mirella Marino; Edith M Marom; Andrew G Nicholson; Meinoshin Okumura; Enrico Ruffini; Paul Van Schil
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

2.  Chemotherapy for invasive thymoma. A 13-year experience.

Authors:  A Fornasiero; O Daniele; C Ghiotto; M Piazza; L Fiore-Donati; F Calabró; F Rea; M V Fiorentino
Journal:  Cancer       Date:  1991-07-01       Impact factor: 6.860

Review 3.  The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond.

Authors:  Alexander Marx; Peter Hohenberger; Hans Hoffmann; Joachim Pfannschmidt; Philipp Schnabel; Hans-Stefan Hofmann; Karsten Wiebe; Berthold Schalke; Wilfred Nix; Ralf Gold; Nick Willcox; Pärt Peterson; Philipp Ströbel
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

Review 4.  Imaging thymoma.

Authors:  Edith M Marom
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

Review 5.  Extended resections for thymic malignancies.

Authors:  Cameron D Wright
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

6.  Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.

Authors:  Giuseppe Giaccone; Arun Rajan; Rita Ruijter; Egbert Smit; Cees van Groeningen; Pancras C W Hogendoorn
Journal:  J Thorac Oncol       Date:  2009-10       Impact factor: 15.609

7.  Advanced stage thymomas and thymic carcinomas: results of multimodality treatments.

Authors:  Marco Lucchi; Marcello Carlo Ambrogi; Leonardo Duranti; Fulvio Basolo; Gabriella Fontanini; Carlo Alberto Angeletti; Alfredo Mussi
Journal:  Ann Thorac Surg       Date:  2005-06       Impact factor: 4.330

8.  Chemotherapy and operation for invasive thymoma.

Authors:  F Rea; F Sartori; M Loy; F Calabrò; A Fornasiero; O Daniele; G Altavilla
Journal:  J Thorac Cardiovasc Surg       Date:  1993-09       Impact factor: 5.209

9.  Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.

Authors:  Michael Ried; Tobias Potzger; Nico Braune; Reiner Neu; York Zausig; Berthold Schalke; Claudius Diez; Hans-Stefan Hofmann
Journal:  Eur J Cardiothorac Surg       Date:  2012-08-10       Impact factor: 4.191

10.  Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.

Authors:  Edward S Kim; Joe B Putnam; Ritsuko Komaki; Garrett L Walsh; Jae Y Ro; Hyung Ju Shin; Mylene Truong; Hojin Moon; Steven G Swisher; Frank V Fossella; Fadlo R Khuri; Waun K Hong; Dong M Shin
Journal:  Lung Cancer       Date:  2004-06       Impact factor: 5.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.